TrialBlood advances2024

OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.

Yuliya Linhares et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.